Oxaliplatin for Colorectal Cancer in the United States: Better Late Than Never

This publication has 20 references indexed in Scilit:

• Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial
  Journal of Clinical Oncology, 2003
• Drug resistance and drug development in multiple myeloma
  Seminars in Oncology, 2002
• Neuroprotective Effect of Reduced Glutathione on Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial
  Journal of Clinical Oncology, 2002
• 8. Aggressive Lymphomas
  Annals of Oncology, 2002
• Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity
  British Journal of Cancer, 2002
• Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences
  Cancer Chemotherapy and Pharmacology, 2002
• High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7)
  European Journal Of Cancer, 2001
• Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
  New England Journal of Medicine, 2000
• Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6)
  European Journal Of Cancer, 1999
• Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines
  Annals of Oncology, 1996